 The FDA has granted a second Breakthrough Device designation to CytoSorbents Corporations NASDAQ: CTSO DrugSorb-ATR Antithrombotic Removal System. The designation covers removing the Direct Oral Anticoagulants DOACs apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of severe perioperative bleeding in cardiothoracic surgery. 